Midas Management Corp Has $522,000 Stake in United Therapeutics Corporation (UTHR)

Midas Management Corp maintained its position in United Therapeutics Corporation (NASDAQ:UTHR) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,025 shares of the biotechnology company’s stock at the end of the second quarter. Midas Management Corp’s holdings in United Therapeutics Corporation were worth $522,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Nomura Asset Management Co. Ltd. increased its stake in United Therapeutics Corporation by 0.3% in the first quarter. Nomura Asset Management Co. Ltd. now owns 12,646 shares of the biotechnology company’s stock valued at $1,712,000 after buying an additional 40 shares during the period. Fisher Asset Management LLC increased its stake in United Therapeutics Corporation by 1.4% in the second quarter. Fisher Asset Management LLC now owns 3,169 shares of the biotechnology company’s stock valued at $411,000 after buying an additional 45 shares during the period. Argent Capital Management LLC increased its stake in shares of United Therapeutics Corporation by 2.4% in the first quarter. Argent Capital Management LLC now owns 2,530 shares of the biotechnology company’s stock worth $343,000 after buying an additional 60 shares during the period. PNC Financial Services Group Inc. increased its stake in shares of United Therapeutics Corporation by 4.8% in the first quarter. PNC Financial Services Group Inc. now owns 2,092 shares of the biotechnology company’s stock worth $284,000 after buying an additional 95 shares during the period. Finally, LS Investment Advisors LLC increased its stake in shares of United Therapeutics Corporation by 2.6% in the first quarter. LS Investment Advisors LLC now owns 3,995 shares of the biotechnology company’s stock worth $541,000 after buying an additional 100 shares during the period.

Shares of United Therapeutics Corporation (NASDAQ:UTHR) traded up 0.95% during trading on Friday, hitting $128.23. 457,333 shares of the stock were exchanged. The company has a market cap of $5.57 billion, a price-to-earnings ratio of 14.87 and a beta of 1.51. United Therapeutics Corporation has a 12-month low of $110.90 and a 12-month high of $169.89. The firm has a 50 day moving average of $130.60 and a 200-day moving average of $135.35.

United Therapeutics Corporation (NASDAQ:UTHR) last released its quarterly earnings data on Thursday, July 27th. The biotechnology company reported ($1.25) EPS for the quarter, missing analysts’ consensus estimates of $3.61 by $4.86. United Therapeutics Corporation had a net margin of 24.18% and a return on equity of 20.96%. The company had revenue of $444.60 million during the quarter, compared to the consensus estimate of $391.53 million. During the same quarter in the prior year, the company posted $4.42 EPS. The company’s revenue for the quarter was up 7.8% compared to the same quarter last year. On average, analysts forecast that United Therapeutics Corporation will post $10.70 earnings per share for the current year.

United Therapeutics Corporation declared that its Board of Directors has authorized a share buyback program on Thursday, April 27th that permits the company to buyback $250.00 million in outstanding shares. This buyback authorization permits the biotechnology company to buy up to 4.6% of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s management believes its shares are undervalued.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by BNB Daily and is the sole property of of BNB Daily. If you are reading this piece of content on another website, it was copied illegally and reposted in violation of US and international trademark and copyright legislation. The original version of this piece of content can be read at https://www.baseball-news-blog.com/2017/08/13/united-therapeutics-corporation-uthr-position-maintained-by-midas-management-corp-updated.html.

Several equities analysts have issued reports on UTHR shares. Zacks Investment Research downgraded shares of United Therapeutics Corporation from a “hold” rating to a “sell” rating in a report on Thursday, July 13th. BidaskClub cut shares of United Therapeutics Corporation from a “hold” rating to a “sell” rating in a research report on Monday, July 31st. ValuEngine upgraded shares of United Therapeutics Corporation from a “buy” rating to a “strong-buy” rating in a research report on Thursday, July 13th. Wedbush reiterated an “outperform” rating and issued a $213.00 target price (down from $229.00) on shares of United Therapeutics Corporation in a research report on Thursday, April 27th. Finally, UBS AG restated a “sell” rating and set a $106.00 price objective on shares of United Therapeutics Corporation in a research report on Thursday, July 6th. Six analysts have rated the stock with a sell rating, seven have issued a hold rating and three have issued a buy rating to the company. United Therapeutics Corporation has an average rating of “Hold” and an average price target of $134.50.

In related news, CEO Martine A. Rothblatt sold 2,176 shares of the stock in a transaction that occurred on Thursday, August 10th. The stock was sold at an average price of $127.11, for a total transaction of $276,591.36. Following the completion of the transaction, the chief executive officer now directly owns 3,245 shares of the company’s stock, valued at $412,471.95. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Christopher Causey sold 590 shares of the stock in a transaction that occurred on Thursday, July 6th. The shares were sold at an average price of $132.61, for a total value of $78,239.90. Following the transaction, the director now directly owns 3,875 shares of the company’s stock, valued at $513,863.75. The disclosure for this sale can be found here. Over the last three months, insiders sold 24,675 shares of company stock valued at $3,181,693. Insiders own 7.80% of the company’s stock.

About United Therapeutics Corporation

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Institutional Ownership by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply